Pathological findings in reduction mammoplasty specimens: A South African perspective by Sofianos, C et al.
RESEARCH
308       April 2015, Vol. 105, No. 4
Breast reduction (reduction mammoplasty) is fre­
quently performed by plastic and breast surgeons to 
relieve macromastia symptoms.[1] In the USA, a 97% 
increase in the number of reduction mammoplas­
ty procedures has been observed.[2] The procedure 
increases both physical and psychological wellbeing and improves 
quality of life for many patients.[3]
Crikelair and Malton[4] published the first reported case of 
occult carcinoma discovered during reduction mammoplasty in 
1959. They described the presence of ductal carcinoma seen on 
microscopic examination of surgical specimens. Interestingly, they 
then published an addendum to their initial report when the patient 
developed another primary tumour in the other breast. Since then, 
as detailed below, many studies have attempted to investigate 
the incidence of occult carcinoma in reduction mammoplasty 
specimens.
Snyderman and Lizardo[5] performed a landmark study investi­
gating the presence of occult carcinoma in reduction mammoplasty 
specimens. They examined 5 008 cases and demonstrated an incidence 
of 0.38%. In 1997, Jansen et al.[6] found an incidence of 0.16% in 
their series of 2 576 patients; however, the study design made use of 
a postal questionnaire sent out to consultant plastic surgeons, so it 
was susceptible to sampling bias. A population­based series study 
in Ontario, Canada, found a significantly lower inci dence (0.06%) 
of breast cancer at the time of reduction mammo plasty.[7] While 
older studies such as this are possibly outdated, given the improved 
awareness of breast malignancy and enhanced clinical and radiological 
techniques used in its detection, in the above series, patients diagnosed 
with breast cancer at the time of reduction mammoplasty were less 
likely to have advanced cancer than the general population and had 
a better 5­year survival rate. Preoperative screening featured both a 
clinical breast examination and mammography.[7]
In South Africa (SA), from which our data are drawn, the latest 
available statistics from the SA National Cancer Registry are from 
2006 and show that the incidence of breast cancer in SA is 0.029%.[8] 
Macromastia is in itself a factor predisposing to breast cancer.[9] 
The increased prevalence of carcinoma of the breast in these women 
suggests that they may ultimately develop breast cancer following 
breast reduction.[10] Surgeons should be mindful of this fact, and 
undertake preoperative screening.[11] If a lesion is detected, the 
recommended triple breast evaluation steps outlined in Table 1 must 
be followed.
Diagnosis of breast cancer prior to reduction mammoplasty is 
vital, as management and treatment options may change signifi­
cantly.[12] A woman would be unlikely to opt to proceed with reduction 
mammoplasty without having both a biopsy and a multidisciplinary 
team decision on the management of malignancy. The diagnosis of 
breast cancer during reduction mammoplasty reduces the number 
of appropriate surgical options available and also complicates further 
treatment of the cancer.[2]
Methods
The worldwide incidence of occult carcinoma in reduction 
mammoplasty specimens is low. No study examining these patho­
logical findings has been performed in SA. As discussed, studies have 
been conducted in developed countries, but this information may not 
be accurately extrapolated to developing countries such as SA.
Study area 
Chris Hani Baragwanath Academic Hospital (CHBAH) is a public 
hospital situated in Soweto, Johannesburg, South Africa. It serves a mostly 
black African, lower­income population of 2.5 million. Mammoplasty 
procedures are performed at CHBAH free of charge to the patient. 
Helen Joseph Hospital (HJH) is a public hospital situated in Westdene, 
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Johannesburg, and serves a population of approximately 198 000 of 
mixed socioeconomic status. Mammoplasty procedures are not provided 
free of charge at HJH, but the cost is lower than that at a private hospital.
Study design
A retrospective record review was performed of all patients who 
had undergone reduction mammoplasty procedures at CHBAH or 
HJH between January 2009 and January 2014, inclusive. Along with 
demographic data, patient histories of breast cancer, findings on 
preoperative screening, surgical techniques and pathological reports 
were recorded.
Inclusion criteria
To be included in the study sample, each patient had to meet 
the following three inclusion criteria: no preoperative history or 
examination suggestive of any breast disease; reduction mammoplasty 
performed on one or both breasts, using standard surgical techniques; 
and surgical specimens submitted for pathological review.
Preoperative screening
A detailed history was obtained, and aimed to identify previous or 
current breast disease and personal or family risk factors for breast 
disease. Screening further included clinical examination of the 
breasts as well as imaging – specifically, breast ultrasound for patients 
<35 years of age, and mammography for those aged ≥35 years. 
Preoperative imaging not only enabled significant breast disorders to 
be identified before surgery, but provided a control for detection of 
abnormalities after surgery had been performed.[13]
Pathological assessment
Pathological findings were categorised into two broad groups: benign 
lesions and malignant lesions. Fibrocystic disease was included 
under benign pathology. Malignant pathology included carcinoma 
in situ. Only cases with at least two random blocks per breast were 
included. All specimens had been submitted to the SA National 
Health Laboratory Service.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) 20.0 (SPSS Inc., 
USA) software program for Macintosh was used in data analysis. 
Descriptive results were expressed as means and standard deviations 
(SDs). Statistical evaluations were performed using the non­parametric 
Mann­Whitney U­test. The level of significance was set at p<0.05.
Ethical approval
Ethical approval was obtained from the Human Research Ethics 
Committee of the University of the Witwatersrand (clearance No. 
M140239).
Results
A total of 209 patients were identified for inclusion in the study. 
Nine were excluded because their operative specimens had not 
been submitted for pathological analysis. The 200 patients included 
were all female, with a mean (SD) age of 37.1 (11.9) years. The 
youngest patient was 20 years of age, and the oldest 84. All patients 
had undergone a preoperative work­up including history­taking, 
clinical examination and imaging. All reductions were performed 
using standard techniques, with 195 procedures being bilateral and 
five unilateral. The mean (SD) weight of specimens submitted for 
pathological review was 1 002.8 (652.1) g.
Benign pathology was observed in 98/200 patients (49%) and 
malignant pathology in four (2%). Specific pathological findings are 
listed in Table 2. Benign pathology was observed at a mean age of 46.5 
years and malignant pathology at a mean of 50.2 years.
The Shapiro­Wilk test of normality revealed that the age and 
average specimen weight variables were not normally distributed. A 
Mann­Whitney U­test showed that age was a variable significantly 
associated with the presence of both benign disease (p<0.0001) and 
malignant disease (p=0.012). No significant difference was found 
when the presence of benign or malignant disease was correlated with 
specimen weight. Furthermore, there was no significant difference 
when specific malignant lesions were compared, probably owing to 
the small sample number.
Discussion
Reduction mammoplasty produces a variable amount of tissue 
that should always be sent for pathological examination.[14] The 
procedure is of both cosmetic and oncological significance.[15] Its 
oncological significance is based primarily on the observation that 
breast cancer risk is reduced proportionate to the amount of breast 
tissue removed during the procedure.[16] Additionally, breast cancer 
encountered before, during, or after reduction mammoplasty requires 
a multidisciplinary approach to treatment, like any other breast cancer.
Malignant pathology was observed in 2% (n=4) of the 200 patients 
in this study. The incidence of occult breast carcinoma in other 
series ranges from 0.06% to 4.6%, with the most recent study in 
2013 reporting a 0.56% rate of malignant pathology (including both 
invasive carcinoma and carcinoma in situ).[17] Differences in incidence 
Table 1. Triple breast evaluation
History Carefully gather a patient history, with the aim of identifying any personal or family history of breast cancer, or any predisposing factors[9]
Clinical examination Undertake a physical examination (including breast and nodal basin examination)[2]
Imaging Undertake imaging, by either a mammogram or breast ultrasound[2,11]
Table 2. Specific benign and malignant lesions
Pathological diagnosis n 
Benign lesions (N=98)









Ductal carcinoma in situ 3
Invasive lobular carcinoma 1
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arise because some studies include patients with previous or current 
breast disease, while in others, carcinoma in situ was not included. In 
addition, the pick­up of abnormal pathology increases in proportion 
to the degree of the pathological analysis.[18] In 1984, Nielsen et al.[19] 
showed through intensive pathological scrutiny of breast specimens 
obtained from autopsy (200 or more blocks per specimen) that 14 ­ 
16% of these specimens had occult carcinoma or carcinoma in situ. 
A future direction for our study would be a prospective investigation 
including a higher number of blocks per specimen to increase the rate 
of pick­up of pathological lesions.
Freedman et al.[20] found that the incidence of both premalignant 
and malignant lesions increased with increasing patient age; this 
trend was also seen in the current study, the significance extending 
to benign lesions as well as premalignant and malignant lesions. 
The malignant conditions encountered were largely (75%) of the 
ductal carcinoma in situ variety. The most common benign lesion 
encountered was fibrocystic change, followed by sclerosing adenosis. 
We found fibroadenoma, classically a condition encountered in 
younger individuals, to be more common among older patients. The 
weight of the specimen was not found to influence the presence of 
benign or malignant disease.
Patients who undergo reduction mammoplasty at CHBAH or HJH 
are followed up at 6 and 12 months. They are given advice regarding 
further screening, and are also followed up as part of SA’s standard 
breast cancer screening programmes. Long­term follow­up of these 
patients would be of value to ascertain the incidence of breast cancer 
in the remaining breast tissue. Furthermore, in countries with a high 
prevalence of HIV/AIDS, variables such as HIV positivity and CD4 
count would be useful data to capture and examine in future research. 
These data were not available for our retrospective review, but could 
be included in future prospective studies.
Every patient in the current study had had preoperative screening, 
despite the scant availability of universal guidelines for preoperative 
assessment and pathological assessment.
All methods of breast reduction allow for good exposure of breast 
parenchyma, and for direct visualisation and palpation of other 
segments; theoretically, any palpable tumour therefore can and 
should be detected at that time.[1] Titley et al.[21] suggested in 1996 that 
surgical specimens be separated clearly into left and right, and that 
a marker stitch be placed in the main specimen, possibly separating 
tissues into quadrants. Since the majority of reduction mammoplasty 
specimens do not have occult carcinoma, it would be difficult to 
convince all surgeons to ink the margins of surgical specimens; 
however, it is reasonable to insist that specimens from women at an 
increased risk of developing breast cancer be inked for orientation.[2]
More recently it has been suggested that patients undergoing 
reduction mammoplasty be stratified according to risk; doing so 
would dictate the setting in which surgery should take place and the 
approach to pathological analysis of the specimen.[15] Table 3 outlines 
the approach to risk stratification and in what settings surgery should 
be done.
Patients diagnosed with breast cancer at the time of reduc tion 
mammoplasty are likely to be treated with a completion mastec­
tomy.[7] The basis of this decision is the rearrangement of tissue 
during the procedure, as well as the possibility of tumour seeding in 
the normal breast. Discovery of a breast carcinoma during or after 
a reduction mammoplasty poses a number of technical challenges: 
a large field of dissection, including a breach of pectoral fascia in 
certain areas; a larger skin incision; and possible contamination 
of the other breast during bilateral procedures.[12] The suggested 
technique, if breast cancer is discovered in pathological examination 
of surgical specimens from reduction mammoplasty, is a completion 
mastectomy that includes pre­existing incisions from the reduction 
mammoplasty procedure.[22] Reduction mammoplasty should not 
be considered a contraindication to sentinel lymph node biopsy, as 
many lymphatic channels remain intact and most breast reduction 
techniques involve incisions on the inferior aspect of the breast.[23]
Many philosophical debates on ethics and informed consent have 
arisen in recent years. In the UK, screening for breast cancer is not 
recommended for any woman under the age of 50.[24] Furthermore, 
the US Preventive Services Task Force’s breast screening recom­
mendations recently indicated that mammography is of no benefit 
for patients under the age of 50.[25] Given these recommendations, 
many young women worldwide who are undergoing reduction mam­
moplasty are in effect undergoing a ‘screening procedure’ without 
their informed consent.[26] Although the incidence of occult carci­
noma among reduction mammoplasty specimens is low, all patients 
undergoing the procedure should be fully informed that the tissue 
will be sent for pathological examination, as doing so allows them to 
prepare for the possibility of receiving news of breast cancer, and to 
be adequately equipped for the decision­making that will follow.[26] 
Indeed, ‘The primary intent of mammoplasty is cosmetic, but it is a 
medical procedure, taking place in a medical setting, and those per­
forming it have a fiduciary obligation towards their patients’ health 
and wellbeing.’[26]
Conclusion
It has been demonstrated that, even in developing countries, it is 
of vital importance that surgeons aim to adequately investigate 
reduction mammoplasty candidates preoperatively and ensure 
that all tissue is submitted for pathological analysis. During the 
informed consent process for the procedure, patients should be fully 
informed of the potential consequences of the pathological analysis 
of surgical specimens obtained. Multidisciplinary approaches to 
Table 3. Risk stratification for reduction mammoplasty patients[14]
Risk group Features
Setting in which surgery should 
take place Approach to specimen
High risk Personal history of breast cancer
BRCA1 or BRCA2 mutations
Previous radiation to the chest
Personal history of cancer syndromes
Pathology and surgical oncology 
services should be available
Margins should be inked and specimens 
orientated and divided into individual 
containers per segment resected
Intermediate risk Family history of breast cancer
Proliferative benign breast lesions
Pathology and surgical oncology 
services should be available
Inking of margins may be omitted 
Low risk Age <30 years
No family history of breast cancer
Surgery may be performed at an 
outpatient centre
Specimen may be sent in two containers: 
left and right breast
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breast cancer treatment should always be included for patients 
undergoing reduction mammoplasty who are diagnosed with breast 
cancer. Age was found to correlate significantly with the presence of 
benign or malignant disease in reduction mammoplasty specimens. 
Further areas of study exist, and the results thereof could increase our 
understanding of the various pathological lesions found in reduction 
mammoplasty specimens.
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